1. United States Diabetes Care Devices Market Outlook to 2018-
Glucose Monitoring and Insulin Delivery
Report Details:
Published:September 2012
No. of Pages: 148
Price: Single User License – US$2500
United States Diabetes Care Devices Market Outlook to 2018- Glucose Monitoring and Insulin
Delivery
Summary
GlobalData’s new report, “United States Diabetes Care Devices Market Outlook to 2018- Glucose
Monitoring and Insulin Delivery” provides key market data on the United States Diabetes Care
Devices market. The report provides value (USD million), volume (units) and average price (USD)
data for each segment and sub-segment within two market categories – Glucose Monitoring and
Insulin Delivery. The report also provides company shares and distribution shares data for each of
the aforementioned market categories. The report is supplemented with global corporate-level
profiles of the key market participants with information on company financials and pipeline
products, wherever available.
This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
- Market size and company share data for Diabetes Care Devices market categories – Glucose
Monitoring and Insulin Delivery.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for
each of the segments and sub-segments within two market categories. Data from 2004 to 2011,
forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the two market categories.
- Global corporate-level profiles of key companies operating within the United States Diabetes
Care Devicesmarket.
- Key players covered include LifeScan, Inc., Medtronic, Inc., Bayer HealthCare AG, F. Hoffmann-
La Roche Ltd., Abbott Laboratories, Becton, Dickinson and Company and others.

2. Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for
strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the United States Diabetes
Care Devices competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to
register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product
distribution – Identify, understand and capitalize.
Get your copy of this report @
http://www.reportsnreports.com/reports/197481-united-states-diabetes-care-devices-market-outlook-to-2018-
glucose-monitoring-and-insulin-delivery.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 11
2.1 What is This Report About? 11
3 Diabetes Care Devices In United States 12
3.1 Diabetes Care Devices, Market Segmentation 12
3.2 Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, 2004-2018 13
3.3 Diabetes Care Devices Market, United States, Revenue Mix ($m), 2011 14
3.4 Diabetes Care Devices Market, United States, Category Contribution (%), 2011 15
3.5 Diabetes Care Devices, United States, Company Share (2010-2011) 22
4 Glucose Monitoring In United States 24
4.1 Glucose Monitoring, Market Segmentation 24
4.2 Glucose Monitoring Market, United States, Revenue Mix ($m), 2011 25
4.3 Glucose Monitoring Market, United States, Segment Contribution (%), 2011 26
4.4 Glucose Monitoring Overall Revenue, (2004-2018) 27
4.4.1 Blood Glucose Meters, Revenue (2004-2018) 31
4.5 Glucose Monitoring Overall Volume (2004-2018) 35
4.5.1 Blood Glucose Meters, Volume (2004-2018) 39
4.6 Glucose Monitoring Average Price (2004-2018) 43
4.7 Glucose Monitoring Distribution Share (2010-2011) 44
4.8 Glucose Monitoring, United States, Company Share (2010-2011) 45
5 Insulin Delivery In United States 47
5.1 Insulin Delivery Market, United States, Revenue Mix ($m), 2011 48

3. 5.2 Insulin Delivery Market, United States, Segment Contribution (%), 2011 49
5.3 Insulin Delivery Overall Revenue, (2004-2018) 50
5.3.1 Insulin Pens, Revenue (2004-2018) 54
5.3.2 Insulin Pumps, Revenue (2004-2018) 58
5.4 Insulin Delivery Overall Volume (2004-2018) 62
5.4.1 Insulin Pens, Volume (2004-2018) 66
5.4.2 Insulin Pumps, Volume (2004-2018) 70
5.5 Insulin Delivery Average Price (2004-2018) 73
5.6 Insulin Delivery Distribution Share (2010-2011) 74
5.7 Insulin Delivery, United States, Company Share (2010-2011) 75
6 Overview of Key Companies in United States Diabetes Care Devices Market 77
6.1 LifeScan, Inc. 77
6.1.1 Company Overview 77
6.1.2 Share in the United States Diabetes Care Devices Market 77
6.2 Medtronic, Inc. 78
6.2.1 Company Overview 78
6.2.2 Share in the United States Diabetes Care Devices Market 78
6.3 Bayer HealthCare AG 79
6.3.1 Company Overview 79
6.3.2 Share in the United States Diabetes Care Devices Market 79
6.4 F. Hoffmann-La Roche Ltd. 80
6.4.1 Company Overview 80
6.4.2 Share in the United States Diabetes Care Devices Market 80
6.5 Abbott Laboratories 81
6.5.1 Company Overview 81
6.5.2 Share in the United States Diabetes Care Devices Market 82
6.6 Becton, Dickinson and Company 83
6.6.1 Company Overview 83
6.6.2 Share in the United States Diabetes Care Devices Market 83
6.7 Eli Lilly and Company 84
6.7.1 Company Overview 84
6.8 Animas Corporation 84
6.8.1 Company Overview 84
6.9 Novo Nordisk A/S 84
6.9.1 Company Overview 84
6.10 Sanofi 85
6.10.1 Company Overview 85
6.11 Insulet Corporation 85
6.11.1 Company Overview 85
6.12 ARKRAY, Inc. 86
6.12.1 Company Overview 86
6.13 B. Braun Melsungen AG 86

4. 6.13.1 Company Overview 86
7 Diabetes Care Devices Market Pipeline Products 87
8 Financial Deals Landscape 93
8.1 Acquisition 93
8.1.1 LifeScan Acquires Calibra Medical 93
8.1.2 Arriva Medical Acquires AmMed Direct For $23 Million 94
8.1.3 ActiveCare To Acquire 4G Biometrics, Healthcare Technology Company 95
8.1.4 DexCom Completes Acquisition Of SweetSpot Diabetes Care For Up To $8.5 Million 96
8.1.5 Arriva Medical Acquires Direct Diabetic Source 98
8.1.6 Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For $36 Million 99
8.1.7 Alere Acquires Arriva Medical From Palm Beach Capital For $83 Million 100
8.2 Partnerships 101
8.2.1 Nextgen Healthcare Enters Into Technology Integration Agreement With Nipro Diagnostics
101
8.2.2 Alere Enters Into Co-Development Agreement With AT&T 102
8.2.3 Telcare Enters Into Licensing Agreement With Diabetech For GlucoDynamix-ADMS 103
8.2.4 Tethys Bioscience Enters Into Technology Integration Agreement With Lose It 104
8.2.5 Juvenile Diabetes Research Foundation Extends Co-Development Agreement With Becton,
Dickinson 105
8.2.6 Juvenile Diabetes Research Foundation Enters Into Co-Development Agreement With
Helmsley Charitable Trust And Medtronic 106
8.2.7 Tandem Diabetes Enters Into Licensing Agreement With DexCom 107
8.2.8 Roche Diagnostics Enters Into Distribution Agreement With DexCom 108
8.2.9 Roche Diagnostics Enters Into Research And Development Agreement With DexCom 109
8.2.10 Pal Health Enters Into Distribution Agreement With Surefit For Xtremityone 110
9 Recent Developments 111
9.1 Strategy And Business Planning 111
9.1.1 Aug 28, 2012: Medtronic Opens Shanghai Innovation Center 111
9.1.2 Aug 09, 2012: Takeda Establishes Development Center In China 112
9.1.3 Jun 26, 2012: Roche To Shut New Jersey Site, Eliminate 1,000 Jobs 112
9.1.4 May 22, 2012: Greatbatch To Establish New Global Headquarters 113
9.1.5 Mar 21, 2012: HealthMed To Expand Portfolio Of Products Beyond Organ Transplantation
114
9.1.6 Feb 27, 2012: Greatbatch Announces Engagement To Advance Medical Device Strategy
114
9.1.7 Jan 26, 2012: Nipro Diagnostics Purchases New Building, Expands Fort Lauderdale
Operations 115
9.1.8 Jan 19, 2012: BD And Mercy/ROi Collaborate To Improve Quality Of Care And Reduce
Costs 115
9.1.9 Oct 19, 2011: Abbott To Separate Into Two Leading Companies In Diversified Medical
Products And Research-Based Pharmaceuticals 116
9.1.10 Oct 13, 2011: Unisense Establishes US Headquarter 118

5. 9.2 Research And Development 119
9.2.1 Jul 17, 2012: Greatbatch To Establish R&D Centre In Singapore 119
9.2.2 Mar 21, 2012: Index Ventures Launches New €150m Life Sciences Fund With Investments
From GSK And Janssen 120
9.2.3 Jan 09, 2012: Bayer HealthCare To Share Lab Space With Start-Up Companies 121
9.3 Legal and Regulatory 122
9.3.1 Jun 29, 2012: Sucampo Pharma Provides Update On Anticipated Arbitration Decision 122
9.3.2 May 30, 2012: Sucampo Announces Change In Date Of Anticipated Arbitration Decision In
Dispute With Takeda 122
9.3.3 Apr 17, 2012: Sanmina-SCI Suzhou, China Facility Receives ISO 13485 Certification For
Medical Devices 122
9.3.4 Mar 30, 2012: Medtronic Reaches Settlement Of Shareholder Class Action 123
9.3.5 Dec 23, 2011: Glancy Binkow Announces Class Action Lawsuit Against Hospira 123
9.3.6 Dec 13, 2011: Medtronic Reaches Settlement With US Department of Justice 123
9.3.7 Nov 22, 2011: Izard Nobel Announces Class Action Lawsuit Against Hospira 124
9.4 Government and Public Interest 125
9.4.1 Jun 28, 2012: American Diabetes Association Applauds US Supreme Court Decision To
Uphold Affordable Care Act 125
9.4.2 Jun 15, 2012: American Diabetes Association Applauds Passage Of Connecticut House Bill
5348 125
9.4.3 Jun 15, 2012: American Diabetes Association Applauds Federal Funding For Diabetes
Research And Prevention 126
9.4.4 Jun 15, 2012: OSA Is Associated With Diabetic Peripheral Neuropathy: Study 127
9.4.5 May 23, 2012: Beta Cell Imaging Could Help Spot Diabetes Earlier: Vanderbilt University
128
9.4.6 Mar 13, 2012: Researchers Identify Optimal Threshold For HbA1c Test For Prediabetes 129
9.4.7 Mar 01, 2012: Diabetes Research Institute Develops Revolutionary Oxygen-Generating
Biomaterial To Enhance Islet Survival 130
9.4.8 Feb 13, 2012: Blood From Periodontal Disease Can Be Used To Screen For Diabetes: NYU
Study 131
9.4.9 Jan 20, 2012: Researchers At Brown University Develops Biochip To Measures Glucose In
Saliva 132
9.4.10 Jan 11, 2012: American Diabetes Association Applauds Revised US State Department
Policy 133
9.4.11 Jan 03, 2012: Maternal Liver Grafts More Tolerable For Children With Rare Disease: UCSF
133
9.4.12 Oct 14, 2011: MannKind To Present At 18th Annual Newsmakers In BioTech Industry
Conference 134
9.4.13 Sep 29, 2011: Research At UC Reveals Hormone Action That Could Lead To Treatments
For Type 2 Diabetes 134
9.4.14 Sep 14, 2011: Medtronic Pledges Action In Advance of United Nations High Level Meeting
On Noncommunicable Diseases 135

6. 9.5 Product News 136
9.5.1 Oct 28, 2011: ARKRAY''s GLUCOCARD Vital And 01 Blood Glucose Meters Are Listed On
DoD Uniform Formulary 136
9.5.2 Jun 29, 2010: Medtronic Announces STAR 3 Trial Results Confirming MiniMed Paradigm
REAL-Time System Achieves Better Glucose Control Than Daily Insulin Injections In Diabetic
Patients 137
9.5.3 Jun 25, 2010: Medtronic Begins Enrollment In ASPIRE Pivotal Study Of MiniMed Paradigm
x54 System 138
9.5.4 Mar 17, 2010: Medtronic Announces FDA Approval Of MiniMed Paradigm REAL-Time Revel
System 138
9.5.5 Aug 05, 2009: Continuous Glucose Monitoring Benefits Even Well-Controlled Type 1
Diabetics 139
9.5.6 Jul 10, 2009: Medtronic Announces Voluntary Recall Of Paradigm Specific Lots Of Quick-Set
Infusion Sets 140
9.5.7 Jun 07, 2009: Medtronic Presents REAL Trend Study Results Of MiniMed Paradigm REAL-
Time System At 69th Annual Scientific Sessions Of The ADA 140
9.5.8 May 05, 2009: Bayer HealthCare Releases CONTOUR Meters In Two Bold New Colors, The
Midnight Blue And Orange Burst 141
10 Appendix 142
10.1 Definitions of Markets Covered in the Report 143
10.1.1 Diabetes Care Devices 143
10.2 Research Methodology 145
10.3 Secondary Research 145
10.4 Primary Research 146
10.5 Models 146
10.6 Forecasts 147
10.7 Expert Panels 147
10.8 GlobalData Consulting 147
10.9 Currency Conversion 147
10.10 Contact Us 147
10.11 Disclaimer 148
1.1 List of Tables
Table 1: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, 2004-2018
13
Table 2: Diabetes Care Devices Market, United States, Category Contribution (%), 2011 15
Table 3: Diabetes Care Devices, United States, Cross-Segment Analysis, 2004-2018 17
Table 4: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, Historic,
2004-2011 19
Table 5: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, Forecast,
2011-2018 21
Table 6: Diabetes Care Devices, United States, Company Share by Revenue ($m), USD

7. Constant, 2010-2011 23
Table 7: Glucose Monitoring Market, United States, Segment Contribution (%), 2011 26
Table 8: Glucose Monitoring, United States, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 28
Table 9: Glucose Monitoring, United States, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 30
Table 10: Blood Glucose Meters, United States, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 32
Table 11: Blood Glucose Meters, United States, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 34
Table 12: Glucose Monitoring, United States, Volume (Units) by Segment, Historic, 2004-2011 36
Table 13: Glucose Monitoring, United States, Volume (Units) by Segment, Forecast, 2011-2018 38
Table 14: Blood Glucose Meters, United States, Volume (Units) by Sub-Segment, Historic, 2004-
2011 40
Table 15: Blood Glucose Meters, United States, Volume (Units) by Sub-Segment, Forecast, 2011-
2018 42
Table 16: Glucose Monitoring, United States, Average Price ($), Historic, 2004-2011 43
Table 17: Glucose Monitoring, United States, Average Price ($), Forecast, 2011-2018 43
Table 18: Glucose Monitoring, United States, Distribution Share by Revenue ($m), USD Constant,
2010-2011 44
Table 19: Glucose Monitoring, United States, Company Share by Revenue ($m), USD Constant,
2010-2011 46
Table 20: Insulin Delivery Market, United States, Segment Contribution (%), 2011 49
Table 21: Insulin Delivery, United States, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 51
Table 22: Insulin Delivery, United States, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 53
Table 23: Insulin Pens, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic,
2004-2011 55
Table 24: Insulin Pens, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
2011-2018 57
Table 25: Insulin Pumps, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic,
2004-2011 59
Table 26: Insulin Pumps, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
2011-2018 61
Table 27: Insulin Delivery, United States, Volume (Units) by Segment, Historic, 2004-2011 63
Table 28: Insulin Delivery, United States, Volume (Units) by Segment, Forecast, 2011-2018 65
Table 29: Insulin Pens, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011 67
Table 30: Insulin Pens, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018 69
Table 31: Insulin Pumps, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011 71
Table 32: Insulin Pumps, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018 72
Table 33: Insulin Delivery, United States, Average Price ($), Historic, 2004-2011 73

8. Table 34: Insulin Delivery, United States, Average Price ($), Forecast, 2011-2018 73
Table 35: Insulin Delivery, United States, Distribution Share by Revenue ($m), USD Constant,
2010-2011 74
Table 36: Insulin Delivery, United States, Company Share by Revenue ($m), USD Constant, 2010-
2011 76
Table 37: Diabetes Care Devices Market Pipeline Products 87
Table 38: LifeScan Acquires Calibra Medical 93
Table 39: Arriva Medical Acquires AmMed Direct For $23 Million 94
Table 40: ActiveCare To Acquire 4G Biometrics, Healthcare Technology Company 95
Table 41: DexCom Completes Acquisition Of SweetSpot Diabetes Care For Up To $8.5 Million 96
Table 42: Arriva Medical Acquires Direct Diabetic Source 98
Table 43: Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For $36 Million
99
Table 44: Alere Acquires Arriva Medical From Palm Beach Capital For $83 Million 100
Table 45: Nextgen Healthcare Enters Into Technology Integration Agreement With Nipro
Diagnostics 101
Table 46: Alere Enters Into Co-Development Agreement With AT&T 102
Table 47: Telcare Enters Into Licensing Agreement With Diabetech For GlucoDynamix-ADMS 103
Table 48: Tethys Bioscience Enters Into Technology Integration Agreement With Lose It 104
Table 49: Juvenile Diabetes Research Foundation Extends Co-Development Agreement With
Becton, Dickinson 105
Table 50: Juvenile Diabetes Research Foundation Enters Into Co-Development Agreement With
Helmsley Charitable Trust And Medtronic 106
Table 51: Tandem Diabetes Enters Into Licensing Agreement With DexCom 107
Table 52: Roche Diagnostics Enters Into Distribution Agreement With DexCom 108
Table 53: Roche Diagnostics Enters Into Research And Development Agreement With DexCom
109
Table 54: Pal Health Enters Into Distribution Agreement With Surefit For Xtremityone 110
1.2 List of Figures
Figure 1: Diabetes Care Devices, Market Segmentation 12
Figure 2: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, 2004-
2018 13
Figure 3: Diabetes Care Devices Market, United States, Revenue Mix ($m), 2011 14
Figure 4: Diabetes Care Devices Market, United States, Category Contribution (%), 2011 15
Figure 5: Diabetes Care Devices, United States, Cross-Segment Analysis, 2004-2018 16
Figure 6: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, Historic,
2004-2011 18
Figure 7: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, Forecast,
2011-2018 20
Figure 8: Diabetes Care Devices, United States, Company Share (%), 2011 22
Figure 9: Glucose Monitoring, Market Segmentation 24

9. Figure 10: Glucose Monitoring Market, United States, Revenue Mix ($m), 2011 25
Figure 11: Glucose Monitoring Market, United States, Segment Contribution (%), 2011 26
Figure 12: Glucose Monitoring, United States, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 27
Figure 13: Glucose Monitoring, United States, Revenue ($m) USD Constant, by Segment,
Forecast, 2011-2018 29
Figure 14: Blood Glucose Meters, United States, Revenue ($m) USD Constant, by Sub-Segment,
Historic, 2004-2011 31
Figure 15: Blood Glucose Meters, United States, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 33
Figure 16: Glucose Monitoring, United States, Volume (Units) by Segment, Historic, 2004-2011 35
Figure 17: Glucose Monitoring, United States, Volume (Units) by Segment, Forecast, 2011-2018
37
Figure 18: Blood Glucose Meters, United States, Volume (Units) by Sub-Segment, Historic, 2004-
2011 39
Figure 19: Blood Glucose Meters, United States, Volume (Units) by Sub-Segment, Forecast,
2011-2018 41
Figure 20: Glucose Monitoring, United States, Company Share (%), 2011 45
Figure 21: Insulin Delivery, Market Segmentation 47
Figure 22: Insulin Delivery Market, United States, Revenue Mix ($m), 2011 48
Figure 23: Insulin Delivery Market, United States, Segment Contribution (%), 2011 49
Figure 24: Insulin Delivery, United States, Revenue ($m) USD Constant, by Segment, Historic,
2004-2011 50
Figure 25: Insulin Delivery, United States, Revenue ($m) USD Constant, by Segment, Forecast,
2011-2018 52
Figure 26: Insulin Pens, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic,
2004-2011 54
Figure 27: Insulin Pens, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast,
2011-2018 56
Figure 28: Insulin Pumps, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic,
2004-2011 58
Figure 29: Insulin Pumps, United States, Revenue ($m) USD Constant, by Sub-Segment,
Forecast, 2011-2018 60
Figure 30: Insulin Delivery, United States, Volume (Units) by Segment, Historic, 2004-2011 62
Figure 31: Insulin Delivery, United States, Volume (Units) by Segment, Forecast, 2011-2018 64
Figure 32: Insulin Pens, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011 66
Figure 33: Insulin Pens, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018 68
Figure 34: Insulin Pumps, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011 70
Figure 35: Insulin Pumps, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018
72
Figure 36: Insulin Delivery, United States, Company Share (%), 2011 75
Figure 37: LifeScan, Inc., Company Share (%),United States Diabetes Care Devices Market, 2011

10. 77
Figure 38: Medtronic, Inc., Company Share (%),United States Diabetes Care Devices Market,
2011 78
Figure 39: Bayer HealthCare AG, Company Share (%),United States Diabetes Care Devices
Market, 2011 79
Figure 40: F. Hoffmann-La Roche Ltd., Company Share (%),United States Diabetes Care Devices
Market, 2011 80
Figure 41: Abbott Laboratories, Company Share (%),United States Diabetes Care Devices Market,
2011 82
Figure 42: Becton, Dickinson and Company, Company Share (%),United States Diabetes Care
Devices Market, 2011 83
Contact: sales@reportsandreports.com for more information.